Directorate Change

For immediate release:

                                  VALIRX PLC                                   

                          ("ValiRx" or the "Company")                          

                  Directorate change and directors' holdings                   

The Board of ValiRx (AIM: VAL) are pleased to announce that non-executive
director, James Nicholas Thorniley, has been appointed non-executive Chairman
with immediate effect. His appointment follows the resignation today of Anthony
Moore as Chairman who has stood down from the Board to focus on other
commercial interests.

Satu Vainikka, CEO of ValiRx, commented:

"Anthony has played an instrumental role in the formation of the Company, its
funding and admission to AIM. Following the completion of the Company's first
year on AIM after the reverse takeover, he felt the timing was right to stand
down. The Board would like to thank him for his contribution to the business
over the last two years."

Further to his resignation, Anthony Moore has informed the Company that he has
today disposed of 100,000 ordinary shares of 6p each in the Company ("Ordinary
Shares") at 12p per share, reducing his shareholding to 275,000 Ordinary Shares
representing 0.87% of the issued ordinary share capital of the Company.

                                  ---ENDS---                                   

About ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos Ltd, Valibio SA and Morphogenesis Inc;

  * Cronos holds licenses to two innovative and potentially market changing
    technologies, GeneICE and HyperGenomics;
   
  * Valibio SA is developing oncology diagnostic products based on
    groundbraking technologies, Hypergenomics and Nucleosomics.
   
  * Morphogenesis Inc. is developing a portfolio of cell therapy products for
    the treatment of chronic disorders. Its most advanced product, being
    ImmuneFxâ„¢ for which it recently received a patent from the US patent
    office.
   
ValiRx is headquartered in London, England.

Further information can be found at www.valirx.com

Contact Details:

      ValiRx Plc            WH Ireland         GTH Communications   
                                                                    
   Dr Satu Vainikka       David Youngman        Toby Hall / Jade    
                                                   Mamarbachi       
                                                                    
 [phone]  [phone]   [phone]